BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38552671)

  • 1. Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With a Blood Test That Meets the Centers for Medicare & Medicaid Services Coverage Decision.
    van den Puttelaar R; Nascimento de Lima P; Knudsen AB; Rutter CM; Kuntz KM; de Jonge L; Escudero FA; Lieberman D; Zauber AG; Hahn AI; Inadomi JM; Lansdorp-Vogelaar I
    Gastroenterology; 2024 Jul; 167(2):368-377. PubMed ID: 38552671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With Blood-Based Biomarkers (Liquid Biopsy) vs Fecal Tests or Colonoscopy.
    Ladabaum U; Mannalithara A; Weng Y; Schoen RE; Dominitz JA; Desai M; Lieberman D
    Gastroenterology; 2024 Jul; 167(2):378-391. PubMed ID: 38552670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests.
    Peterse EFP; Meester RGS; de Jonge L; Omidvari AH; Alarid-Escudero F; Knudsen AB; Zauber AG; Lansdorp-Vogelaar I
    J Natl Cancer Inst; 2021 Feb; 113(2):154-161. PubMed ID: 32761199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
    Ladabaum U; Mannalithara A
    Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Multitarget Stool DNA Testing vs Colonoscopy or Fecal Immunochemical Testing for Colorectal Cancer Screening in Alaska Native People.
    Redwood DG; Dinh TA; Kisiel JB; Borah BJ; Moriarty JP; Provost EM; Sacco FD; Tiesinga JJ; Ahlquist DA
    Mayo Clin Proc; 2021 May; 96(5):1203-1217. PubMed ID: 33840520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening.
    Lansdorp-Vogelaar I; Goede SL; Bosch LJW; Melotte V; Carvalho B; van Engeland M; Meijer GA; de Koning HJ; van Ballegooijen M
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):504-512.e11. PubMed ID: 28733262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare.
    Ladabaum U; Mannalithara A; Brill JV; Levin Z; Bundorf KM
    Am J Gastroenterol; 2018 Dec; 113(12):1836-1847. PubMed ID: 29904156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer.
    Gini A; Zauber AG; Cenin DR; Omidvari AH; Hempstead SE; Fink AK; Lowenfels AB; Lansdorp-Vogelaar I
    Gastroenterology; 2018 Feb; 154(3):556-567.e18. PubMed ID: 29102616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population.
    Ebner D; Kisiel J; Barnieh L; Sharma R; Smith NJ; Estes C; Vahdat V; Ozbay AB; Limburg P; Fendrick AM
    J Med Econ; 2023; 26(1):1219-1226. PubMed ID: 37752872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
    Phisalprapa P; Supakankunti S; Chaiyakunapruk N
    J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
    [No Abstract]   [Full Text] [Related]  

  • 11. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
    Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
    Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies.
    Sharaf RN; Ladabaum U
    Am J Gastroenterol; 2013 Jan; 108(1):120-32. PubMed ID: 23247579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimated impact and value of blood-based colorectal cancer screening at varied adherence compared with stool-based screening.
    Kisiel JB; Fendrick AM; Ebner DW; Ozbay AB; Vahdat V; Estes C; Limburg PJ
    J Med Econ; 2024; 27(1):746-753. PubMed ID: 38686394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries.
    Naber SK; Knudsen AB; Zauber AG; Rutter CM; Fischer SE; Pabiniak CJ; Soto B; Kuntz KM; Lansdorp-Vogelaar I
    PLoS One; 2019; 14(9):e0220234. PubMed ID: 31483796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population.
    Fisher DA; Karlitz JJ; Jeyakumar S; Smith N; Limburg P; Lieberman D; Fendrick AM
    J Med Econ; 2021; 24(1):654-664. PubMed ID: 33902366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force.
    Knudsen AB; Zauber AG; Rutter CM; Naber SK; Doria-Rose VP; Pabiniak C; Johanson C; Fischer SE; Lansdorp-Vogelaar I; Kuntz KM
    JAMA; 2016 Jun; 315(23):2595-609. PubMed ID: 27305518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population.
    Knudsen AB; Lansdorp-Vogelaar I; Rutter CM; Savarino JE; van Ballegooijen M; Kuntz KM; Zauber AG
    J Natl Cancer Inst; 2010 Aug; 102(16):1238-52. PubMed ID: 20664028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
    Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History.
    Cenin DR; Naber SK; de Weerdt AC; Jenkins MA; Preen DB; Ee HC; O'Leary PC; Lansdorp-Vogelaar I
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):10-21. PubMed ID: 31748260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Simulated Outcomes Between Stool- and Blood-Based Colorectal Cancer Screening Tests.
    Fendrick AM; Vahdat V; Chen JV; Lieberman D; Limburg PJ; Ozbay AB; Kisiel JB
    Popul Health Manag; 2023 Aug; 26(4):239-245. PubMed ID: 37466476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.